Volume 25, Number 5—May 2019
Research
Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
Lawrence Mbuagbaw
, Lorenzo Guglielmetti, Catherine Hewison, Nyasha Bakare, Mathieu Bastard, Eric Caumes, Mathilde Fréchet-Jachym, Jérôme Robert, Nicolas Veziris, Naira Khachatryan, Tinatin Kotrikadze, Armen Hayrapetyan, Zaza Avaliani, Holger J. Schünemann, and Christian Lienhardt
, Lorenzo Guglielmetti, Catherine Hewison, Nyasha Bakare, Mathieu Bastard, Eric Caumes, Mathilde Fréchet-Jachym, Jérôme Robert, Nicolas Veziris, Naira Khachatryan, Tinatin Kotrikadze, Armen Hayrapetyan, Zaza Avaliani, Holger J. Schünemann, and Christian Lienhardt
Table 2
Baseline characteristics of participants in study of bedaquiline treatment for multidrug-resistant tuberculosis*
| Variable | Cohort |
Total, n = 537 | ||||
|---|---|---|---|---|---|---|
| South Africa, n = 195 | France, n = 45 | Janssen, n = 205 | Armenia, n = 62 | Georgia, n = 30 | ||
| Mean age, y (SD) |
35.8 (11.2) |
37.4 (12.1) |
34.9 (12.2) |
41.6 (12.6) |
38.7 (11.9) |
36.4 (11.8) |
| Sex, no. (%) | ||||||
| M | 98 (50.3) | 36 (80.0) | 132 (64.4) | 55 (88.7) | 21 (70.0) | 342 (63.7) |
| F |
97 (49.7) |
9 (20.0) |
73 (35.6) |
7 (11.3) |
9 (30.0) |
195 (36.3) |
| Mean no. months on BDQ (SD) | 5.8 (1.2) | 12.3 (7.0) | 5.9 (1.1) | 5.6 (1.6) | 6.0 (1.3) | 6.37 (2.3) |
| No. on BDQ >6 mo (%) |
4 (2.1) |
32 (71.1) |
0.0 |
0.0 |
0.0 |
36 (6.7)† |
| Mean total treatment duration, mo (SD) |
14.9 (6.7) |
19.4 (4.7) |
21.8 (7.6) |
20.2(7.4) |
14.0 (6.1) |
18.47 (6.9)† |
| No. (%) with treatment outcome available | 101 (51.8)† | 45 (100.0) | 205 (100.0) | 62 (100.0) | 30 (100.0) | 443 (82.5) |
| No. (%) HIV positive‡ | 120 (63.1) | 2 (4.4) | 8 (4.0) | 4 (6.5) | 1 (3.3) | 135 (25.1) |
| No. (%) on antiretroviral therapy |
110 (56.4) |
2 (4.4) |
0.0 |
0 |
0 |
112 (20.9) |
| Type of TB, no. (%) | ||||||
| Pulmonary | NR | 44 (97.8) | 205 (100.0) | 62 (100.0) | 30 (100.0) | 341 (99.7) |
| Extrapulmonary |
NR |
8 (17.8) |
0 |
0 |
0 |
8 (2.3) |
| No. (%) with previous TB treatment | NR | 34 (75.6) | 193 (94.1) | 62 (100.0) | 29 (96.7) | 271 (79.2) |
| No. (%) with previous second-line TB treatment | NR | 27 (60.0) | 177 (86.3) | 62 (100.0) | 29 (96.7) | 295 (86.3) |
| No. (%) with lung cavities on chest radiograph |
NR |
39 (86.7) |
135 (65.8) |
55 (88.7) |
24 (80.0) |
253 (73.9) |
| Resistance profile, no. (%)§ | ||||||
| MDR TB | 0 | 7 (15.6) | 93 (45.4) | 6 (9.7) | 0 | 100 (18.6) |
| MDR TB + FQ | 73 (37.4) | 8 (17.8) | 31 (15.1) | 26 (41.9) | 5 (16.7) | 147(27.3) |
| MDR TB + INJ | 29 (14.9) | 6 (13.3) | 13 (6.3) | 7 (11.3) | 0 | 55 (10.2) |
| XDR TB | 77 (39.5) | 24 (53.3) | 37 (18.0) | 23 (37.1) | 25 (83.3) | 188 (35.0) |
*BDQ, bedaquiline; FQ, fluoroquinolone; INJ, injectable; MDR, multidrug resistant; NR, not reported; TB, tuberculosis; XDR, extensively drug resistant.
†Missing data: South Africa = 15.
‡Missing data: South Africa = 17; Janssen (drug manufacturer) = 7.
§Missing data: South Africa = 16; Janssen (drug manufacturer) = 31.
Page created: April 18, 2019
Page updated: April 18, 2019
Page reviewed: April 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.